AZD0486 加利妥昔单抗治疗既往未经治疗的滤泡性淋巴瘤患者的研究
一项 III 期、多中心、随机、开放标签研究,旨在比较 AZD0486 加利妥昔单抗与化疗加利妥昔单抗对既往未经治疗的滤泡性淋巴瘤受试者的疗效和安全性
This is a global, randomised, Phase III, multicentre, open-label study evaluating the efficacy, safety and the degree of added benefit of the Surovatamig (AZD0486) plus rituximab combination compared to Investigator's choice of 3 standard immunochemotherapy regimen, conducted in participants with untreated FL.
研究概览
详细说明
The study consists of 2 sequential parts.
-
Safety Run-in - this part will compare dose levels of Surovatamig (AZD0486) in combination with rituximab in order to establish the RP3D.
-
Phase III - The Phase III part will assess the superiority of Surovatamig (AZD0486) at RP3D in combination with rituximab, compared to Investigator's choice between 3 standard chemoimmunotherapy regimens. Phase 3 consists of 3 arms
- Arm A: treatment with Surovatamig plus rituximab Schedule A
- Arm B: treatment with Surovatamig plus rituximab Schedule B
- Arm C (Comparator arm): one of the following standard regimens per Investigator's choice: R-CVP + rituximab maintenance, R-CHOP + rituximab maintenance or B-R + rituximab maintenance
研究类型
注册 (估计的)
阶段
- 第三阶段
联系人和位置
学习联系方式
- 姓名:AstraZeneca Clinical Study Information Center
- 电话号码:1-877-240-9479
- 邮箱:information.center@astrazeneca.com
学习地点
-
-
-
Beijing、中国、100730
- 招聘中
- Research Site
-
Beijing、中国、100044
- 招聘中
- Research Site
-
Beijing、中国、100142
- 招聘中
- Research Site
-
Changchun、中国、130021
- 招聘中
- Research Site
-
Changsha、中国、410013
- 招聘中
- Research Site
-
Chengdu、中国、610078
- 招聘中
- Research Site
-
Chongqing、中国、400030
- 招聘中
- Research Site
-
Fuzhou、中国、350001
- 招聘中
- Research Site
-
Guangzhou、中国、510060
- 招聘中
- Research Site
-
Guangzhou、中国、510100
- 招聘中
- Research Site
-
Guangzhou、中国、510000
- 招聘中
- Research Site
-
Hangzhou、中国、310022
- 尚未招聘
- Research Site
-
Hangzhou、中国、310003
- 招聘中
- Research Site
-
Harbin、中国、150081
- 招聘中
- Research Site
-
Hefei、中国、230031
- 招聘中
- Research Site
-
Lanzhou、中国、730000
- 招聘中
- Research Site
-
Nanchang、中国、330006
- 招聘中
- Research Site
-
Nanchang、中国、330029
- 招聘中
- Research Site
-
Nanjing、中国、210029
- 招聘中
- Research Site
-
Nanning、中国、530021
- 招聘中
- Research Site
-
Shandong、中国、250117
- 招聘中
- Research Site
-
Shanghai、中国、200065
- 招聘中
- Research Site
-
Shanghai、中国、20032
- 招聘中
- Research Site
-
Shenyang、中国、110001
- 招聘中
- Research Site
-
Shenyang、中国、110004
- 招聘中
- Research Site
-
Shijiazhuang、中国、054001
- 招聘中
- Research Site
-
Suzhou、中国、215006
- 招聘中
- Research Site
-
Tianjin、中国、300020
- 招聘中
- Research Site
-
Wenzhou、中国、325000
- 招聘中
- Research Site
-
Wuhan、中国、430079
- 招聘中
- Research Site
-
Xi'an、中国、710114
- 招聘中
- Research Site
-
Xiamen、中国、361003
- 招聘中
- Research Site
-
Zhengzhou、中国、450000
- 招聘中
- Research Site
-
Zhengzhou、中国、450008
- 招聘中
- Research Site
-
-
-
-
-
Aalborg、丹麦、9100
- 撤销
- Research Site
-
Copenhagen、丹麦、2100
- 招聘中
- Research Site
-
Odense C、丹麦、5000
- 招聘中
- Research Site
-
Roskilde、丹麦、4000
- 撤销
- Research Site
-
-
-
-
Manitoba
-
Winnipeg、Manitoba、加拿大、R3E 0V9
- 招聘中
- Research Site
-
-
Nova Scotia
-
Halifax、Nova Scotia、加拿大、B3H 2Y9
- 招聘中
- Research Site
-
-
Ontario
-
Barrie、Ontario、加拿大、L4M 6M2
- 撤销
- Research Site
-
Hamilton、Ontario、加拿大、L8V 5C2
- 招聘中
- Research Site
-
Oshawa、Ontario、加拿大、L1G 2B9
- 招聘中
- Research Site
-
Toronto、Ontario、加拿大、M5G 1X6
- 招聘中
- Research Site
-
-
Quebec
-
Chicoutimi、Quebec、加拿大、G7H 5H6
- 招聘中
- Research Site
-
Montreal、Quebec、加拿大、H4J 1C5
- 招聘中
- Research Site
-
Québec、Quebec、加拿大、G1J 1Z4
- 招聘中
- Research Site
-
Saint-Jérôme、Quebec、加拿大、J7Z 2V4
- 招聘中
- Research Site
-
-
-
-
-
Budapest、匈牙利、1122
- 撤销
- Research Site
-
Budapest、匈牙利、1088
- 撤销
- Research Site
-
Debrecen、匈牙利、4032
- 尚未招聘
- Research Site
-
Győr、匈牙利、9024
- 尚未招聘
- Research Site
-
Kaposvár、匈牙利、7400
- 尚未招聘
- Research Site
-
Nyíregyháza、匈牙利、4400
- 撤销
- Research Site
-
Pécs、匈牙利、7624
- 尚未招聘
- Research Site
-
Szeged、匈牙利、6725
- 尚未招聘
- Research Site
-
-
-
-
-
Delhi、印度、110029
- 尚未招聘
- Research Site
-
Delhi、印度、110085
- 招聘中
- Research Site
-
Gurugram、印度、122002
- 尚未招聘
- Research Site
-
Kolkata、印度、700160
- 招聘中
- Research Site
-
Nashik、印度、422002
- 招聘中
- Research Site
-
Surat、印度、396007
- 招聘中
- Research Site
-
Thiruvananthapuram、印度、695011
- 招聘中
- Research Site
-
-
-
-
-
Changhua、台湾、50006
- 招聘中
- Research Site
-
Kaohsiung City、台湾、80756
- 招聘中
- Research Site
-
Kaohsiung City、台湾、833
- 招聘中
- Research Site
-
Lukang Township、台湾、505029
- 招聘中
- Research Site
-
Tainan、台湾、704
- 招聘中
- Research Site
-
Taipei、台湾、106
- 招聘中
- Research Site
-
-
-
-
-
Ankara、土耳其(türkiye)、6200
- 尚未招聘
- Research Site
-
Ankara、土耳其(türkiye)、6620
- 尚未招聘
- Research Site
-
Istanbul、土耳其(türkiye)、34890
- 尚未招聘
- Research Site
-
Istanbul、土耳其(türkiye)、34010
- 尚未招聘
- Research Site
-
Izmir、土耳其(türkiye)、35340
- 撤销
- Research Site
-
-
-
-
-
Porto Alegre、巴西、90035-003
- 招聘中
- Research Site
-
São Paulo、巴西、04501-000
- 招聘中
- Research Site
-
São Paulo、巴西、05652-900
- 招聘中
- Research Site
-
-
-
-
-
Berlin、德国、10967
- 尚未招聘
- Research Site
-
Berlin、德国、13353
- 尚未招聘
- Research Site
-
Deggendorf、德国、94469
- 尚未招聘
- Research Site
-
Düsseldorf、德国、40479
- 尚未招聘
- Research Site
-
Göttingen、德国、37075
- 尚未招聘
- Research Site
-
Hamburg、德国、20246
- 尚未招聘
- Research Site
-
Heidelberg、德国、69120
- 尚未招聘
- Research Site
-
Jena、德国、07747
- 尚未招聘
- Research Site
-
Karlsruhe、德国、76133
- 尚未招聘
- Research Site
-
Kiel、德国、24105
- 尚未招聘
- Research Site
-
Lübeck、德国、23538
- 尚未招聘
- Research Site
-
Magdeburg、德国、39120
- 尚未招聘
- Research Site
-
Minden、德国、32429
- 尚未招聘
- Research Site
-
München、德国、81377, DE
- 尚未招聘
- Research Site
-
Münster、德国、48129
- 尚未招聘
- Research Site
-
Regensburgs、德国、93049
- 尚未招聘
- Research Site
-
Würzburg、德国、97080
- 尚未招聘
- Research Site
-
-
-
-
-
Bologna、意大利、40138
- 尚未招聘
- Research Site
-
Milan、意大利、20141
- 尚未招聘
- Research Site
-
Reggio Emilia、意大利、42100
- 尚未招聘
- Research Site
-
-
-
-
-
Brno、捷克语、625 00
- 尚未招聘
- Research Site
-
Hradec Králové、捷克语、500 05
- 尚未招聘
- Research Site
-
Prague、捷克语、12808
- 尚未招聘
- Research Site
-
-
-
-
-
Bunkyō City、日本、113-8677
- 招聘中
- Research Site
-
Chiba、日本、260-8717
- 招聘中
- Research Site
-
Chuo-shi、日本、409-3898
- 招聘中
- Research Site
-
Fukuoka、日本、812-8582
- 招聘中
- Research Site
-
Hirakata-shi、日本、573-1191
- 招聘中
- Research Site
-
Kobe、日本、650-0047
- 招聘中
- Research Site
-
Kumamoto、日本、860-8556
- 招聘中
- Research Site
-
Kurashiki-shi、日本、710-8602
- 招聘中
- Research Site
-
Kyoto、日本、602-8566
- 招聘中
- Research Site
-
Kōtoku、日本、135-8550
- 招聘中
- Research Site
-
Minatoku、日本、105-8470
- 招聘中
- Research Site
-
Okayama、日本、700-8558
- 招聘中
- Research Site
-
Osaka、日本、541-8567
- 招聘中
- Research Site
-
Sapporo、日本、060-8638
- 招聘中
- Research Site
-
Sapporo、日本、003-0006
- 招聘中
- Research Site
-
Sunto-gun、日本、411-8777
- 招聘中
- Research Site
-
Toyoake-shi、日本、470-1192
- 招聘中
- Research Site
-
Yamagata、日本、990-9585
- 招聘中
- Research Site
-
Yokohama、日本、241-8515
- 招聘中
- Research Site
-
-
-
-
-
Brussels、比利时、1070
- 尚未招聘
- Research Site
-
Brussels、比利时、1090
- 尚未招聘
- Research Site
-
Ghent、比利时、9000
- 尚未招聘
- Research Site
-
Mechelen、比利时、2800
- 尚未招聘
- Research Site
-
-
-
-
-
Bayonne、法国、64100
- 尚未招聘
- Research Site
-
La Tronche、法国、38700
- 撤销
- Research Site
-
Lille、法国、59037
- 尚未招聘
- Research Site
-
Montpellier、法国、34295
- 尚未招聘
- Research Site
-
Saint-Cloud、法国、92210
- 尚未招聘
- Research Site
-
Vandœuvre-lès-Nancy、法国、54511
- 撤销
- Research Site
-
-
-
-
-
Gdansk、波兰、80-214
- 尚未招聘
- Research Site
-
Gliwice、波兰、44-102
- 撤销
- Research Site
-
Katowice、波兰、40-519
- 尚未招聘
- Research Site
-
Krakow、波兰、30-727
- 尚未招聘
- Research Site
-
Lublin、波兰、20-081
- 撤销
- Research Site
-
Lublin、波兰、20-090
- 暂停
- Research Site
-
Warsaw、波兰、02-781
- 尚未招聘
- Research Site
-
Wroclaw、波兰、50-019
- 尚未招聘
- Research Site
-
Wroclaw、波兰、53-439
- 撤销
- Research Site
-
-
-
-
-
San Juan、波多黎各、00918
- 招聘中
- Research Site
-
-
-
-
-
Bangkok、泰国、10330
- 招聘中
- Research Site
-
Bangkok、泰国、10700
- 招聘中
- Research Site
-
Chiang Mai、泰国、50200
- 招聘中
- Research Site
-
Khon Kaen、泰国、40002
- 招聘中
- Research Site
-
-
-
-
-
Clayton、澳大利亚、3168
- 尚未招聘
- Research Site
-
Darlinghurst、澳大利亚、2010
- 招聘中
- Research Site
-
Garran、澳大利亚、2605
- 招聘中
- Research Site
-
Heidelberg、澳大利亚、3084
- 招聘中
- Research Site
-
Macquarie University、澳大利亚、2109
- 招聘中
- Research Site
-
Nedlands、澳大利亚、6009
- 招聘中
- Research Site
-
-
-
-
-
Falun、瑞典、79182
- 撤销
- Research Site
-
Uppsala、瑞典、75185
- 撤销
- Research Site
-
-
-
-
Alabama
-
Huntsville、Alabama、美国、35805
- 招聘中
- Research Site
-
-
Alaska
-
Anchorage、Alaska、美国、99508
- 招聘中
- Research Site
-
-
Arizona
-
Phoenix、Arizona、美国、85054
- 招聘中
- Research Site
-
-
California
-
Clovis、California、美国、93611
- 尚未招聘
- Research Site
-
Los Alamitos、California、美国、90720
- 招聘中
- Research Site
-
San Diego、California、美国、92121
- 尚未招聘
- Research Site
-
Santa Monica、California、美国、90404
- 尚未招聘
- Research Site
-
-
Colorado
-
Aurora、Colorado、美国、80045
- 撤销
- Research Site
-
-
Connecticut
-
New Haven、Connecticut、美国、06510
- 招聘中
- Research Site
-
-
Delaware
-
Newark、Delaware、美国、19713
- 尚未招聘
- Research Site
-
-
Florida
-
Jacksonville、Florida、美国、32224
- 招聘中
- Research Site
-
-
Georgia
-
Atlanta、Georgia、美国、30322
- 尚未招聘
- Research Site
-
Macon、Georgia、美国、31201
- 招聘中
- Research Site
-
-
Illinois
-
Evanston、Illinois、美国、60201
- 尚未招聘
- Research Site
-
Peoria、Illinois、美国、61615
- 尚未招聘
- Research Site
-
-
Indiana
-
Fort Wayne、Indiana、美国、46804
- 招聘中
- Research Site
-
-
Iowa
-
Des Moines、Iowa、美国、50309
- 尚未招聘
- Research Site
-
Iowa City、Iowa、美国、52242
- 尚未招聘
- Research Site
-
-
Kentucky
-
Lexington、Kentucky、美国、40536
- 尚未招聘
- Research Site
-
Louisville、Kentucky、美国、40207
- 尚未招聘
- Research Site
-
-
Louisiana
-
Baton Rouge、Louisiana、美国、70808
- 尚未招聘
- Research Site
-
-
Maryland
-
Baltimore、Maryland、美国、21201
- 尚未招聘
- Research Site
-
Bethesda、Maryland、美国、20817
- 招聘中
- Research Site
-
Columbia、Maryland、美国、21044
- 尚未招聘
- Research Site
-
-
Massachusetts
-
Boston、Massachusetts、美国、02114
- 尚未招聘
- Research Site
-
Boston、Massachusetts、美国、02215
- 尚未招聘
- Research Site
-
-
Michigan
-
Ann Arbor、Michigan、美国、48109
- 尚未招聘
- Research Site
-
Detroit、Michigan、美国、48201
- 撤销
- Research Site
-
Ypsilanti、Michigan、美国、48197
- 尚未招聘
- Research Site
-
-
Minnesota
-
Rochester、Minnesota、美国、55905
- 招聘中
- Research Site
-
Saint Paul、Minnesota、美国、55102
- 尚未招聘
- Research Site
-
-
Missouri
-
Chesterfield、Missouri、美国、63017
- 尚未招聘
- Research Site
-
Springfield、Missouri、美国、65807
- 招聘中
- Research Site
-
-
New Jersey
-
Hackensack、New Jersey、美国、07601
- 尚未招聘
- Research Site
-
New Brunswick、New Jersey、美国、08901
- 尚未招聘
- Research Site
-
-
New York
-
Albany、New York、美国、12206
- 招聘中
- Research Site
-
Brooklyn、New York、美国、11220
- 尚未招聘
- Research Site
-
Mineola、New York、美国、11501
- 尚未招聘
- Research Site
-
New Hyde Park、New York、美国、11042
- 尚未招聘
- Research Site
-
New York、New York、美国、10065
- 招聘中
- Research Site
-
New York、New York、美国、10032
- 招聘中
- Research Site
-
New York、New York、美国、10016
- 招聘中
- Research Site
-
-
North Carolina
-
Charlotte、North Carolina、美国、28204
- 招聘中
- Research Site
-
Charlotte、North Carolina、美国、28204
- 尚未招聘
- Research Site
-
Wilmington、North Carolina、美国、28401
- 尚未招聘
- Research Site
-
Winston-Salem、North Carolina、美国、27103
- 尚未招聘
- Research Site
-
-
Ohio
-
Blue Ash、Ohio、美国、45242
- 尚未招聘
- Research Site
-
Cincinnati、Ohio、美国、45219
- 尚未招聘
- Research Site
-
Columbus、Ohio、美国、43210
- 尚未招聘
- Research Site
-
-
Oregon
-
Eugene、Oregon、美国、97401
- 尚未招聘
- Research Site
-
Portland、Oregon、美国、97227
- 撤销
- Research Site
-
-
Pennsylvania
-
Pittsburgh、Pennsylvania、美国、15232
- 尚未招聘
- Research Site
-
-
Tennessee
-
Nashville、Tennessee、美国、37203
- 招聘中
- Research Site
-
-
Texas
-
Austin、Texas、美国、78705
- 尚未招聘
- Research Site
-
Lubbock、Texas、美国、79430
- 尚未招聘
- Research Site
-
Shenandoah、Texas、美国、77380
- 尚未招聘
- Research Site
-
Tyler、Texas、美国、75702
- 尚未招聘
- Research Site
-
-
Utah
-
Salt Lake City、Utah、美国、84112
- 尚未招聘
- Research Site
-
-
Virginia
-
Fairfax、Virginia、美国、22031
- 尚未招聘
- Research Site
-
Richmond、Virginia、美国、23219
- 尚未招聘
- Research Site
-
-
Washington
-
Tacoma、Washington、美国、98405
- 招聘中
- Research Site
-
-
Wisconsin
-
Madison、Wisconsin、美国、53792
- 尚未招聘
- Research Site
-
Milwaukee、Wisconsin、美国、53226
- 尚未招聘
- Research Site
-
-
-
-
-
Helsinki、芬兰、00029
- 撤销
- Research Site
-
Kuopio、芬兰、70029
- 撤销
- Research Site
-
Tampere、芬兰、33520
- 撤销
- Research Site
-
-
-
-
-
London、英国、SE5 9RS
- 招聘中
- Research Site
-
London、英国、EC1M6BQ
- 招聘中
- Research Site
-
Newcastle upon Tyne、英国、NE7 7DN
- 招聘中
- Research Site
-
Norwich、英国、NR4 7UY
- 招聘中
- Research Site
-
Nottingham、英国、NG5 1PB
- 招聘中
- Research Site
-
Plymouth、英国、PL6 8DH
- 招聘中
- Research Site
-
Southampton、英国、SO16 6YD
- 撤销
- Research Site
-
-
-
-
-
Barcelona、西班牙、08035
- 尚未招聘
- Research Site
-
Barcelona、西班牙、8036
- 撤销
- Research Site
-
El Palmar、西班牙、30120
- 撤销
- Research Site
-
Girona、西班牙、17007
- 尚未招聘
- Research Site
-
Las Palmas de Gran Canaria、西班牙、35020
- 撤销
- Research Site
-
Madrid、西班牙、28041
- 尚未招聘
- Research Site
-
Madrid、西班牙、28040
- 撤销
- Research Site
-
Oviedo、西班牙、33011
- 撤销
- Research Site
-
Pamplona、西班牙、31008
- 撤销
- Research Site
-
Santander、西班牙、39008
- 尚未招聘
- Research Site
-
-
-
-
-
Busan、韩国、49201
- 招聘中
- Research Site
-
Busan、韩国、49241
- 招聘中
- Research Site
-
Goyang-si、韩国、10408
- 招聘中
- Research Site
-
Jeonnam、韩国、519-763
- 招聘中
- Research Site
-
Seoul、韩国、03080
- 招聘中
- Research Site
-
Seoul、韩国、06351
- 招聘中
- Research Site
-
Seoul、韩国、05505
- 招聘中
- Research Site
-
Seoul、韩国、03722
- 招聘中
- Research Site
-
Seoul、韩国、06591
- 招聘中
- Research Site
-
-
-
-
-
Hong Kong、香港、999077
- 招聘中
- Research Site
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Participant must be at least 18 years of age, inclusive, at the time of signing the ICF.
- Histologically confirmed diagnosis of classic FL per WHO 2022 classification
- ECOG performance status of 0 to 2
- No prior systemic lymphoma-directed therapy
- Need for systemic treatment meeting at least 1 GELF criteria
- FDG-avid and measurable disease
- Stage II to IV and FLIPI 2-5 [Phase III only]
- Adequate liver, hematological, renal and cardiac function.
The above is a summary, other inclusion criteria details may apply
Exclusion Criteria:
- Follicular large B-cell lymphoma (WHO 2022 classification), formerly Follicular lymphoma Grade 3B (WHO 2016 classification) or suspicion for histologic transformation to high-grade/aggressive lymphoma
- Contra-indication to BR, RCVP, and R-CHOP
- Participants with or history of CNS lymphoma
- History of a clinically relevant CNS medical condition or pathology that required treatment in the preceding year, is currently symptomatic or that which the treating investigator considers to have the potential to interfere with the evaluation of safety
- Presence of >5000 circulating lymphoma cells
- Active or uncontrolled infection (including EBV) requiring systemic therapy and which places participant at unacceptable risk if he/she were to participate in the study. If a participant has a history of COVID-19 within 1 month of C1D1 or contracts COVID while on study treatment, participant must have 2 consecutive negative tests (PCR testing is preferable) performed at least 48 hours apart prior to resuming dosing. All symptoms related to COVID-19 infection should have fully resolved before initiating or resuming treatment
- Known history of hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS)
The above is a summary, other exclusion criteria details may apply
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Rituximab, Surovatamig - A
Surovatamig regimen A plus rituximab |
a fully human bispecific monoclonal IgG4 antibody
其他名称:
|
|
实验性的:Rituximab, Surovatamig - B
Surovatamig regimen B plus rituximab |
a fully human bispecific monoclonal IgG4 antibody
其他名称:
|
|
有源比较器:Chemoimmunotherapy
Investigator's choice between 3 standard immunochemotherapy regimen (R-CHOP, R-CVP, or B-R followed by rituximab maintenance) |
Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone Rituximab, Cyclophosphamide, Vincristine and Prednisone Bendamustine, Rituximab |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
SRI Primary: Incidence, nature and severity of AEs and SAEs. Incidence and nature of study drug discontinuations, dose reductions, and dose delays due to AEs
大体时间:Up to 10 years
|
Frequency, severity, and relationship to study drug of AEs and SAEs; dose modifications; changes in physical examination and safety procedures. |
Up to 10 years
|
|
SRI Primary: Determination of the recommended Phase III dose (RP3D)
大体时间:Up to 1 year
|
The RP3D will be the dose of Surovatamig selected for the Phase 3 part based on safety data compiled during the safety run-in part |
Up to 1 year
|
|
Phase 3 Dual Primary: To demonstrate the superiority of Surovatamig plus rituximab compared to Investigator's choice of SoC chemoimmunotherapy
大体时间:Up to 10 years
|
PFS, based on Lugano 2014 Response Criteria, as assessed by BICR. |
Up to 10 years
|
|
Phase 3 Dual Primary: To demonstrate the superiority of Surovatamig plus rituximab compared to Investigator's choice of SoC chemoimmunotherapy
大体时间:Up to 10 years
|
ORR at EoI, based on Lugano 2014 Response Criteria, as assessed by BICR. |
Up to 10 years
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Safety Run in and Phase 3: ORR at EoI (Investigator assessed)
大体时间:Up to 10 years
|
ORR defined as the proportion of participants achieving either a PR or CR at End of Induction based on Lugano 2014 Response Criteria |
Up to 10 years
|
|
Safety Run In and Phase 3: CR Rate
大体时间:Up to 10 years
|
CR rate is defined as the proportion of participants achieving a CR at any time as based on Lugano 2014 Response Criteria |
Up to 10 years
|
|
Safety Run In and Phase 3: CR at EoI
大体时间:Up to 10 years
|
Proportion of participants achieving CR at End of Induction based on Lugano 2014 Response Criteria |
Up to 10 years
|
|
Safety Run In and Phase 3: DoR
大体时间:up to 10 years
|
DoR will be defined from the time of first response until progression based on Lugano 2014 criteria, or death due to any cause |
up to 10 years
|
|
Safety Run In and Phase 3: PFS (Investigator assessed)
大体时间:Up to 10 years
|
PFS (Investigator assessed) is defined as time from randomization until disease progression based on Lugano 2014 Response Criteria or death due to any cause |
Up to 10 years
|
|
Safety Run In and Phase 3: OS
大体时间:Up to 10 years
|
OS is defined as time until the date of death |
Up to 10 years
|
|
Phase 3: CR rate at 30 months (CR30)
大体时间:Up to 30 months
|
Proportion of participants in CR rate at 30 months (CR30) based on Lugano 2014 Response Criteria |
Up to 30 months
|
|
Phase 3: Time to First Subsequent Therapy or Death (TFST)
大体时间:Up to 10 Years
|
TFST will be defined as the time from randomization until the start date of first subsequent anti-lymphoma therapy or death due to any cause |
Up to 10 Years
|
|
Phase 3: Time from randomisation to second progression or death (PFS2)
大体时间:Up to 10 Years
|
PFS2 will be defined as the time from randomization until the earliest of the progression event, after first subsequent therapy, or death due to any cause |
Up to 10 Years
|
合作者和调查者
赞助
调查人员
- 首席研究员:Chan Cheah, MBBS FRACP FRCPA DMSc、Sir Charles Gairdner Hospital (SCGH)
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
关键字
其他研究编号
- D7401C00001
- 2023 (美国 NIH 拨款/合同)
- 2023-510098-33-00 (注册表标识符:CTIS (EU))
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
IPD 共享时间框架
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
IPD 共享访问标准
When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information
IPD 共享支持信息类型
- 研究方案
- 树液
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.